SynVaccine

About:

SynVaccine develops preventive viral vaccines for various major human pathogens.

Top Investors: EASME - EU Executive Agency for SMEs, Sapir Venture Partners

Description:

SynVaccine develops preventive viral vaccines for various major human pathogens. It owns licenses for disruptive technologies that enable the computational rational design of viral genomes and physical DNA editing of viral vaccine genome libraries. Tuval Ben Yehezkel founded SynVaccine in 2013. It has its headquarters in Tel Aviv in Israel.

Total Funding Amount:

$1.76M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Tel Aviv, Tel Aviv, Israel

Founded Date:

2013-01-01

Contact Email:

info(AT)SynVaccine.com

Founders:

Tuval Ben Yehezkel

Number of Employees:

1-10

Last Funding Date:

2018-09-23

IPO Status:

Private

Industries: